KAUST and the Saudi Food and Drug Authority (SFDA) have partnered to develop a new method using nuclear magnetic resonance (NMR) to detect adulterants in olive oil. The method aims to identify and quantify vegetable oils mixed with olive oil, addressing concerns about the mislabeling of olive oil in the Saudi market. KAUST's comprehensive suite of NMR machines was critical for the project. Why it matters: This collaboration enhances food safety and quality control in Saudi Arabia, a major olive oil importer, and helps to ensure consumers receive authentic, high-quality products.
Researchers from KAUST, King Faisal Specialist Hospital, and collaborators have developed a new method to predict cardiometabolic disease risk in underrepresented ethnic populations using genetic information and public databases. The study focused on Arab communities and created a framework to determine polygenic scores for more accurate heart disease prediction. The framework was validated using records of over 5,000 Arab patients, demonstrating that genetic risk complements conventional risk factors. Why it matters: This research addresses a critical gap in genomic data for non-European populations, potentially leading to more effective and personalized healthcare strategies in the Arab world and beyond.
KAUST researchers, in collaboration with the Salk Institute and Altos Labs, have identified a class of RNA (LINE-1) that, when compromised, leads to accelerated aging, as seen in progeria. They devised an antisense RNA strategy to block the aberrant function of L1 RNA, reversing the disease in mice and patient-derived cells. Published in Science Translational Medicine, the research suggests that targeting LINE-1 RNA could treat progeroid syndromes and other age-related diseases. Why it matters: This RNA-based approach provides a potential therapeutic avenue for treating premature aging diseases and extending human health span in the region and globally.
KAUST researchers are exploring the link between nutrition and brain-energy metabolism to address cognitive decline, dementia, and Alzheimer’s disease. Dr. Pierre Magistretti and Dr. Johannes le Coutre are collaborating on ways to merge brain-energy metabolism research into the field of nutrition. They published an article entitled “Goals in Nutrition Science 2015-2020” in the journal Frontiers in Nutrition. Why it matters: This research could lead to nutritional interventions to hinder or prevent cognitive decline, offering a new approach beyond traditional drug treatments.
KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
Juan Carlos Izpisua Belmonte from the Salk Institute discussed aging and regenerative medicine at the KAUST 2019 Winter Enrichment Program. His team is combining gene editing and stem cell technologies to grow rat organs in mice and human cells in pig and cattle embryos. The Salk team is collaborating with KAUST to rejuvenate organs using noncoding RNAs and small metabolites. Why it matters: This research collaboration between KAUST and the Salk Institute explores innovative approaches to address age-related diseases and organ regeneration, with potential long-term impacts on healthcare in the region.
KAUST researchers have identified a protein complex of HuR and YB1 that stabilizes messenger RNA during muscle-fiber formation. The complex protects RNA as it carries muscle-forming code through the cell. Further research aims to elucidate the individual roles of each protein in the stabilization process. Why it matters: Understanding this RNA-stabilizing complex could lead to new therapies for muscle recovery and the prevention of muscle-related pathologies.
Professor Eran Segal presented The Human Phenotype Project, a longitudinal cohort study with over 10,000 participants. The project aims to identify molecular markers and develop prediction models for disease using deep profiling techniques including medical history, lifestyle, blood tests, and microbiome analysis. The study provides insights into drivers of obesity, diabetes, and heart disease, identifying novel markers at the microbiome, metabolite, and immune system level. Why it matters: Such large-scale phenotyping initiatives could inform personalized medicine approaches relevant to the Middle East's specific health challenges.